MUSCLE & NERVE

P288

STIFF PERSON SYNDROME
Patricia Mohadeb, Eliana Cavassa, Gabriel Vasquez, Graciela Barbuzza, Pablo Jorrat, Angeles Schteinschneider. FLENI, Raúl Carrea Institute of Investigaciones Neurológicas, Argentina

Introduction: Stiff-person syndrome (SP) is an uncommon disorder characterized by progressive muscle stiffness, rigidity, and painful spasms involving the axial muscles and proximal portion of lower limbs, resulting in severely impaired ambulation. Phenomena may occur with dysautonomic manifestations

In some occasions it is associated with type 1 diabetes mellitus, or Myasthenia Gravis, showing a pathogenic feature in common.

The diagnosis is usually late, confirmed by the presence of continuous activity of motor unit in paraspinal muscles and in lower limbs in the EMG.

SP presents favorable response to symptomatic and immunomodulatory treatment.

Purpose: We described a patient with clinical and neurophysiological diagnosis of Stiff Person Syndrome detailing the evolution, their clinical characteristics and treatment.

Material and methods: A healthy 13-year-old boy, who started asthenia, with stiffness, rigidity, hypertonia, painful spasms and dyssynergic movements.

Results: We found activity of continuous motor unit in EMG / neuromotonia that affects the muscles of both proximal and distal limbs. Mild sensory and motor polyradiculopathy. Post-synaptic neuromuscular transmission compromise. CK 300 IU/L. Antibodies antiperoxidase positive, high levels of TSH, and antibodies anti GAD positive in CSF, negative in blood. Antibodies antichannel of potassium negative in blood and CSF. Other studies were negative discard paraneoplastic syndrome and other autoimmune diseases. Normal brain and spinal cord MRI.

We started treatment with intravenous pulses of gamma globulin and oral carbamazepine with good response.

Conclusions: The diagnosis of this rare autoimmune variant of the disease allowed the establishment of appropriate therapy. Early recognition and initiation of treatment resulted in noticeable improvement.

P289

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY SECONDARY (CIDP) TO INFLAMMATORY BOWEL DISEASE (IBD) AND ASSOCIATED TO VITAMIN B12 DEFICIENCY
Fernanda Veiga de Goez1, 2, Gabriela Rochedo Villegas2, Rita Farias Oliveira1, Julia Valeriano de Almeida1, Andre Felipe Pinto Duarte1, Eugenia Figueiredo Costa de Lacerda1, Fernandes Figueira Institute, Rio de Janeiro, Brazil; 2Adão Pereira Nunes State Hospital, Rio de Janeiro, Brazil

Introduction: CIDP is characterized by symmetrical weakness in both proximal and distal muscles that progressively increases for more than two months. It may be associated to auto-immune and infectious conditions. We report a case in which the diagnosis of CIDP had led to a diagnosis of IBD, although the first hypothesis was Vitamin B12 deficiency.

Methods: Case report and literature review on the theme.

Case Description: Twelve-year-old boy was admitted with four-week weakness in the lower limbs without any sensitive alteration or pain. He had a history of chronic diarrhea since age 4, associated with malnutrition and recurrent bronchospasm. His exam showed gait instability, lower limbs weakness and absence of deep tendon reflexes of both legs. After four weeks hospitalized, evolved with loss of gait and tactile sensitive alteration, worsening bronchospasm and pneumonia. He had Vitamin B12 deficiency, macrocytic anemia, elevated muscle enzymes, normal CSF and hyperintense signal of the conus medullaris on the MRI. The electromyography showed motor-sensitive chronic demyelinating polyradiculoneuropathy with axonal predominance. After hydroxycobalamin reposition, he had a slight improvement, but only got better after corticosteroid pulse therapy. On corticosteroid suspension, at the follow up, his diarrhoea returned and colonoscopy demonstrated colonstenosis suggesting IBD.

Conclusion/Discussion: CIDP is an underdiagnosed and potentially treatable disease. In our case, although we do not have a nerve biopsy, the clinical pattern and findings on electromyography, besides the response to corticosteroid, can assure the diagnosis of CIDP, especially considering the association with IBD.

P290

ATYPICAL CLINICAL AND HISTOLOGICAL PRESENTATIONS IN PATIENTS WITH MUTATIONS ON THE RYR1 GENE
Cristiane Araújo Martins, Osório Abat Neto, Marco Antonio Veloso Albuquerque, Jocelyne Laporte, Umbertina Conte Reed, Anne Rutkowski, Carsten Bönemann, Edmar Zanetti. Universidade de São Paulo, Brazil

The ryanodine receptor gene (RYR1) encodes the sarcoplasmic reticulum calcium release channel RYR1. RYR1 mutations cause susceptibility to malignant hyperthermia (MH) and various congenital myopathy subtypes (congenital fiber-type disproportion, centronuclear myopathy, central core myopathy and multinucleincore myopathy). Here we report clinical, pathologic and genetic features of three patients from two families with RYR1 mutations and atypical clinical and histological phenotypes. The first case is an 18-year-old female patient with stable and generalized muscle weakness, atrophy and skeletal deformities since the first months of life. Her muscle biopsy showed an intense dystrophic process without specific structural defects, and the initial diagnosis was congenital muscular dystrophy. She had the homozgyous mutation: c.122T>C. The second and third patients are two siblings with neonatal hypotonia, motor developmental delay, proximal weakness, calf hypertrophy, normal CK, no ophthalmoplegia and muscle biopsy compatible with centronuclear myopathy. They are compound heterozygous for two RYR1 mutations: one frameshift deletion, c.6797-6_6798del, and a missense c.9892G>A. Our findings support the clinical and histological variability associated with mutations on RYR1 gene, and confirm previous studies that indicate the need to investigate RYR1 mutations in patients with congenital muscular dystrophies or centronuclear myopathies with no genetic confirmation.

P292

POLYSOMNOGRAPHIC ABNORMALITIES IN CHILDREN WITH DUCHENNE MUSCULAR DYSTROPHY
Carla Rojas1, 2, Alejandra Hernández1, 2, Jocelyn Gutiérrez1, 2, Daniela Castillo1, 2, Mónica Foncoso1, 2, Susana Lara1, 2, Carola Peña1, 2, Verónica Sáez1, 2. Servicio de Neuropsiquiatría Infantil, Hospital Clínico San Borja-Arrarán, Chile; 2Facultad de Medicina Campus Centre, Universidad de Chile, Chile

Introduction: Duchenne Muscular Dystrophy (DMD) is a progressive neuromuscular disease of X-linked recessive inheritance caused by a defect in the dystrophin gene. Sleep-disordered breathing is common in these children, being ten times more prevalent than general population. The objective of this study is to analyze the polysomnographic characteristics in children with DMD.

Methods: Cross-sectional study of 29 patients with DMD who underwent a polysomnogram between 2005-2011. Results: Total of 29 patients, mean age 9 years (2-18), 20/29 (69%) with preserved ambulation, of these, 19 being treated with corticosteroids: 18 prednisone, 1 deflazacort). 9/29 (31%) had lost gait (mean age 13 years), of these, 7 receiving corticosteroids (6 prednisone, 1 deflazacort). 3/29 were users of non-invasive ventilation (NIV). 13/29 (45 %) had reduced sleep onset latency, 14/29 (48%) decreased sleep efficiency, 8/29 (27%) with sleep fragmentation. 13/29 (44%) with increased supraspinal sleep and 11/29 (37%) decreased REM sleep. Respiratory disturbance index (RDI) was increased in 18/29 (62%), 6/18 showed obstructive apneas and hypoapneas, 11/18 central apnoeas and 2/18 a mixed pattern. Of the 9 patients in wheelchair, 3 had an increased RDI: 2/29 with PCO2<53 at the time of the exam. Snoring was present in 7/29 (24%), of which two were associated with obstructive events. Mean baseline oxygen saturation was 97% and desaturation <90% present in 13/29 (45%) patients.

Conclusions: The prevalence of sleep-disordered breathing in children with DMD is relevant. In this study the wheelchair-bound
patients didn’t experience more respiratory events than patients who maintained ambulation. The number of patients receiving NIV was low.

**P293**

**THE INVESTIGATION OF GENETICS, SERUM BIOCHEMISTRY AND PATHOLOGY IN DUCHENNE MUSCULAR DYSTROPHY**

Jianxiang Liao, Chunxi Han. Pediatricneurology, Shenzhen Children’s Hospital, China

**Objective:** To investigate the mutation of DMD gene in children, the dynamic of serum CK and transaminase and the correlation between the two enzymes of DMD, DMD muscle pathology, and the correlation with the age.

**Methods:** 177 boys with DMD were prospectively studied.

**Results:** (1) By MLPA assay, the deletion mutation was account for 71.17% of DMD and the duplication mutations was account for 10.43%, no gene mutations had been detected in 18.40%. Of 30 children whose gene mutations was not been found, 10 were found DMD gene point mutations with next-generation sequencing technology. (2) The CK, AST, ALT activity in infants with DMD were significantly increased more than the normal 10,7,5 times respectively, and were maintained until the age of 8, then gradually declined with age increasing. Enzymes showed than the normal 10,7,5 times respectively, and were maintained until the age increasing. Enzymes showed a linear correlation between CK and AST (r=0.817, p<0.01) or CK and ALT (r=0.669, p<0.01) levels. (3) During the infant period of DMD, there were pathological changes, mainly as atrophy and hypertrophy of muscle fibers. At the late stage, there was little number of muscle fibers, fatty connective tissue proliferation. The elder the more serious.

**Conclusion:** (1) The deletion mutation of DMD gene is the main type of gene mutation. (2) Serum CK, AST, ALT level can reflect the DMD occurences and progress, and provide an important basis for the early diagnosis of DMD. (3) The severity of clinical illness and pathological changes is associated with the course of the disease and the age of muscle biopsy.

**P294**

**CLINICAL OF DIFFERENT PHENOTYPES WITH SPINAL MUSCULAR ATROPHY IN CHILDREN**

Ping Yuan, Li Jiang. Department of Neurology, Children’s Hospital of Chongqing Medical University

**Objective:** To compare the clinical characteristics of spinal muscular atrophy (SMA) in children within different phenotypes.

**Methods:** Totally 66 cases were enrolled in this study. The comparisons were performed in clinical manifestation, changes of electrophysiology, genetic test of homozygous deletions of survival motor neuron 1 gene (SMN1) and follow-up study. The statistics analysis was done by SPSS software for Windows.

**Results:** 63.3% of SMA I patients were characterized by glossopharyngeal paralysis and 30.3% by paradoxical breathing, while the rate ratios were much higher in those with family history (80.0%, 50.0%) of which the age onset were younger (1st month). For patients type II and type III, muscle fibrillation and deformity were more common and functional abilities of some patients might improved naturally. EMG in 73.3% of the patients suggests a motor neuron disease. There was no difference between 3 groups, age factor excluded. Approximately 90.5% of the patients in our cohort lacked both copies of SMN1. There was no significant difference in the deletion frequency or subtypes among the 3 groups.

**Conclusions:** Pulmonary cares are essential for SMA I with family histories in particular. Clinical manifestation of SMA II and SMA III are of great heterogeneity for which a period of follow-up is necessary and differential diagnosis should pay more attention. There is no significant difference in the deletion frequency among the subtypes in electrophysiology and gene tests.

**P295**

**A CHILD WITH ANTI-GQ1b SYNDROME PRESENTING WITH COMPLETE OPHTHALMOPLEGIA AND UNILATERAL FACIAL PALSY**

Puneet Jain1, Susanshi Sharma2, SatinderAneja3, HinaKaur4. Division of Pediatric Neurology, Department of Pediatrics, Lady Harding Medical College and Associated Kalawati Saran Children’s Hospital, New Delhi, India; 2Department of Ophthalmology, Hamdard Institute of Medical Sciences & Research, Hamdard University, New Delhi, India

**Introduction:** The classical phenotype of Miller Fisher syndrome is characterized by ophthalmoplegia, ataxia and areflexia. However, less extensive forms have been described. We report a child with positive anti-GQ1b antibodies with unusual clinical findings.

**Methods:** The clinical records of a child with positive anti-GQ1b antibodies were reviewed and reported.

**Results:** A 14-years-old boy presented with headache, double vision and vomiting for 7 days. There was no history of fever, gait disturbances, altered sensorium or difficulty in swallowing. He had a viral respiratory infection 15 days prior to onset of symptoms. Examination revealed complete ophthalmoplegia, right lower-motor-neuron facial palsy, no limb weakness or cerebellar signs and normal fundus. CSF examination was normal with negative oligoclonal bands. MRI brain was normal. Electrophysilogical studies done in second week of illness showed normal limb nerve conduction studies, low CMAP amplitude of right facial nerve, abnormal blink reflex and negative repetitive nerve stimulation test. The neostigmine challenge test was negative. Lyme disease serology was negative. Anti-GQ1b antibodies were positive with negative Anti-GM1, -GM2, -GM3, -GD1a, -GD1b, -GT1b antibodies. The child was managed conservatively. The child showed complete recovery after 3 months.

**Conclusions:** The patients with positive anti-GQ1b antibodies who do not demonstrate the full complement of the Miller Fisher syndrome triad have been reported previously. However, unilateral facial palsy has not been reported previously. This report further expands the phenotypic spectrum of anti-GQ1b syndrome.

**P296**

**LIMB GIRDLE MYASTHENIA: AN UNCOMMON, TREATABLE CAUSE OF PROXIMAL MUSCLE WEAKNESS IN CHILDREN**

Ramesh Konuru, Lokesh Lingappa, Niket Shah. Rainbow Hospital for Women and Children, Hyderabad, India

**Introduction:** Limb girdle myasthenia (LGM) is rare variant of myasthenia and differs from common forms in terms of presentation and distribution of weakness.

**Presentation:** Child1: 8 year-old previously healthy boy presented with severe abdominal pain aggravated on attempting to sit, stand/walk since 10 days without diurnal variation; difficulty in walking, getting up from floor since 4 days. Examination revealed hip girdle, truncal and neck flexor weakness and Gowers’ sign. No facial, bulbar/extra-ocular weakness. Sinusous gait was noted when he started walking.

Child2: 11 year, developmentally normal boy presented with severe pain in lower limbs and abdomen, difficulty in sitting, standing/walking since 15 days. He had 4-5 such episodes in past 2 years, improved spontaneously over 7-10 days with asymptomatic period of 3-4 months. Examination-similar to child1.

**Management:** Electrolytes, Thyroid profile, CPK, Urine-Porphobilinogen, ANA, Anti-AchR and Anti-Mus Antibody, CT chest were normal. NCS: Normal. Repetitive Nerve Stimulation Test: 60% & 90% decrement in nasalis, trapezius in child 1 and 2 respectively. Both showed dramatic improvement following IV Neostigmine, and continued on oral pyridostigmine.

**Discussion:** LGM is rare form of MG with prominent proximal muscle weakness, little/no ocular, bulbar or facial weakness. Most autoimmune LGM present after third decade and associated with thymoma. Episodic long-term fluctuations (precipitated by febrile illnesses) and absent diurnal fluctuations is characteristic. Cholinesterase inhibitors (pyridostigmine), corticosteroids (in acquired cases) are mainstay of therapy, with some cases requiring IV steroids, IVIG and/or immunomodulation.

**Conclusion:** LGM is rare treatable neuromuscular disorder. High index of suspicion helps in early diagnosis.

**P297**

**COGNITIVE ASSESSMENT IN CHILDREN WITH DUCHENNE MUSCULAR DYSTROPHY**

Karthik Muthusamy, Maya Mary Thomas, Mathew Alexander, Anirudha George. Department of Neurological Sciences, Christian Medical College, Vellore, Tamilnadu, India

**Introduction:** One third of children with Duchenne muscular dystrophy (DMD) have IQ (Intelligence Quotient) below 70, with a specific profile of cognitive affection and behavioural problems. There is paucity of reports from developing countries.
**P298**

**UNUSUAL NEUROIMAGING FINDINGS IN TWO FAMILIES WITH GIANT AXONAL NEUROPATHY**

Suvasni Sharma,1 Puneet Jain,1 Mahesh Kamate,1 Virupaxi Hattiholi,2 Anita Mahadevan,1 Bijoy Patra,2 Satinder Aneja.1 Division of Pediatric Neurology, Suvasini Sharma,1 Puneet Jain,1 Mahesh Kamate,1 Virupaxi Hattiholi,2 Anita Mahadevan,1 Bijoy Patra,2 Satinder Aneja.1 Division of Pediatric Neurology, 1Department of Pediatrics, KLE University's JNMC, Belgaum, Karnataka, India; 2Department of Radiology, KLE Mahadevan4, Bijoy Patra 1, Satinder Aneja. 1Division of Pediatric Neurology, Suvasini Sharma 1, Puneet Jain 1, Mahesh Kamate 2, Virupaxi Hattiholi 3, Anita 0.001). Twenty percent had mild mental retardation, 50% had borderline age at enrolment was 9.52 years. The mean IQ was 78.3 (SD - 9.01) and 30% had average intelligence (DSM IV criteria). Mean performance IQ was higher than verbal IQ. MRS showed reduced NAA in cerebellum which has not been described previously in literature. There is also increase in the incidence of cognitive impairment in children with deletion towards 3' end of the gene. There was more than expected association of behavioural problems, learning difficulties, sleep disorders and EEG abnormalities in children with DMD.

**Conclusion:** DMD children have high incidence of cognitive and behavioural impairment which is under recognized and has specific profile of affection. Cognitive assessment and therapy needs to be a part of integral approach in management. This area needs further research to elucidate the pathophysiology of the disease.

**Method:** A pretest post test experimental design was used. Caregivers of 36 children with DMD attending neuromuscular disorders clinic of a tertiary referral center for Neurology were studied. All the children had the diagnosis of DMD confirmed by genetic analysis or the absence of dystrophin. Inclusion criteria were: males, in the age range of 4 - 13 years. Caregivers included fathers (19), mothers (17) or both in age range of 27 – 43 yrs. All the parents received individualized intervention based on the psycho social conceptualization of chronic disease by Rolland (1987) targeting specific areas of psychosocial needs identified, caregiver knowledge & attitude, burden of care giving and coping.

**Result:** The program was effective in increasing the Knowledge, attitude and wellbeing, and there was reduction in Family burden. There was shifting of coping strategies from emotional avoidant to active problem focused coping. The limitations of the study and its implications for practice, training and research will be discussed.

**Conclusion:** Parents will benefit from psychosocial intervention to help them develop coping skills to meet their children's needs and their own.

**P300**

**ARRAY-CGH TECHNOLOGY IN THE DISCOVERY OF X-CHROMOSOME COPY NUMBER VARIANTS IN MALE PATIENTS WITH MENTAL RETARDATION SYNDROMES**


**Introduction:** Array comparative genomic hybridization (aCGH) is a high throughput and high resolution technique for the detection of chromosomal copy number variations (CNVs) in the form of deletions, amplifications and gains. Mental retardation is a genetically heterogeneous disorder and more than 90 genes for this disorder have been found on the X chromosome alone. CNVs of X-chromosome (X-CNVs) may be a significant cause of mental retardation in male patients. In this study, the application of this technology has enabled the detection of X-CNVs in males with mental retardation.

**Methods:** aCGH was performed on patients presented with non-syndromic mental retardation from Pantai Hospital Kuala Lumpur, Malaysia using the Oxford Gene Technology (OGT) microarray platform to identify CNVs and their location on the chromosome.

**Results:** Three patients have been identified to have CNVs at a specific region in chromosome X (Xq21.1). Of the three patients, two show a variant duplication resulting in an extra genetic material, while one has a deletion.

**Discussion:** The region of X-CNVs detected encompasses the MAGT1 (Magnesium transporter protein 1) gene. MAGT1 is involved in N-glycosylation through its association with N-oligosaccharyltransferase and in Mg2+ transport in epithelial cells. Based on a study conducted by Molinari et al. (2008), a mutation in the MAGT1 gene was identified in an Australian family where 4 out of 5 children suffered from mild to severe X-linked mental retardation.

**Conclusion:** This shows that aCGH technology can help in the identification of the clinically relevant X-CNVs in males with mental retardation syndromes.

**P301**

**SINDROME SOMATOMORFO POSTERIOR A LA VACUNACIÓN CONTRA LA HEPATITIS B NOTIFICADO COMO ESAVI Y SU IMPACTO EN LA VACUNACIÓN CONTRA LA HEPATITIS B EN ICA, PERÚ**

Inés Caro-Kahn1,1,1 Luis Suárez-Ognio1,2, Hermínio Hernandez2,3, MaríaTizona1, Jorge Uchuya1. 1Instituto Nacional del Niño, Peru; 2Comisión Nacional de Evaluación de ESAVI, Peru; 3Facultad de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru, Peru; 1Universidad Peruana Cayetano Heredia, Peru, 1Escuela de Medicina de Inmunología, Ministerio de Salud, Peru; 1Universidad Peruana, Heredia, Peru, 1Escuela de Medicina, Ministerio de Salud, Peru

**Introduction:** En el año 2007, el Ministerio de Salud organizó una campaña nacional de vacunación contra la hepatitis B con el objetivo de inmunizar a la mayor parte de la población. Reportamos la evaluación de un caso notificado como ESAVI y su impacto sanitario en un departamento del Perú.

**Métodos:** El sistema de vigilancia recibió la notificación de un Evento Supuestamente Atribuido a la Vacunación o Inmunización (ESAVI)
produced luego de la vacunación contra la hepatitis B. El caso fue evaluado por clínicos del Instituto Nacional de Salud del Niño (INSN) y por el Comité Nacional Asesor para la Clasificación de casos de EASVI.

Descripción del caso: Adolescente mujer de 14 años que presenta cefalea intensa y agitación psicomotriz después de diez minutos de la vacunación. Es hospitalizada y diagnosticada de “encefalitis post vacunal”, siendo luego transferida al INSN. La preevaluación del caso produciéndose alarma en la población. Las autoridades políticas suspendieron la campaña de vacunación. La paciente fue evaluada clínicamente y a través de exámenes de laboratorio, resonancia magnética y electroencefalograma, con lo cual el Comité de EASVI clasificó el caso como Síndrome Somatomorfo y como evento no relacionado a la vacuna.

Discusión: La evaluación integral identificó problemas psicológicos y sociales de fondo que incluían acoso sexual y maltrato. La vigilancia de EASVI permitió el conocimiento del caso y la clasificación final. El error diagnóstico inicial como “encefalitis post-vacunal” ocasionó una inadecuada respuesta política y de la presentante, produciéndose un impacto sanitario negativo. Las coberturas de vacunación para hepatitis B y para otras vacunas cayeron a niveles críticos por más de un año en el departamento de Ica.

Métodos: Reportamos los casos de poliomielitis paralítica asociados a las dos vacunaciones de OPV en el periodo 2009-2011. Se realizaron estudios antígenicos en muestras de líquido cefalorraquídeo (LCR) en los dos casos reportados. Se realizó electrodiagnóstico y la identificación de ADN del virus utilizando la técnica de reacción en cadena de la polimerasa (PCR).

Resultados: Se reportaron dos casos de parálisis infantil en el periodo 2009-2011. En el primer caso, la paciente presentó un cuadro de fiebre, mialgias y cefalea después de la vacunación. La exploración neurológica reveló una parálisis flaccida en las extremidades inferiores. En el segundo caso, la paciente presentó un cuadro de fiebre, cefalea y vómitos después de la vacunación. La exploración neurológica reveló una parálisis flaccida en las extremidades superiores.

Conclusiones: Los dos casos reportados no presentaron signos de una respuesta adversa a la vacuna. Sin embargo, la vigilancia intensiva permitió el diagnóstico temprano y la implementación de medidas de control en el ámbito local. Es necesario realizar estudios adicionales para determinar la causa real de estos casos y establecer medidas de prevención adecuadas.

P302
POLIOMIELITIS AGUDA VACUNAL EN EL PERÚ: REPORTE DE CINCO CASOS Y ANÁLISIS DEL IMPACTO SOCIAL Y SANITARIO ENTRE LOS AÑOS 2009 Y 2011

Inés Caro-Kahn1, Luis Suárez-Ugno2, René Leiva-Rosado3, MaríaLicona1, Ibey Chuiy2, Washington Toledo4, Brenda Calzón-Mejía5, Patricia Campos O1, Mario Martínez2. Instituto Nacional del Niño, Peru; Comisión Nacional de Evaluación de EASVI, Peru; UPC Ministerio de Salud, Peru; Estrategia Sanitaria de Inmunizaciones, Ministerio de Salud, Peru; Dirección General de Epidemiología, Ministerio de Salud, Peru; Organización Panamericana de la Salud. Miembro comité revisor parásitos flacida.

Introducción: La Vacuna de Poliovirus Oral (OPV en inglés) permitió la erradicación del virus salvaje de la AMÉRICA en 1994. Se sabe que la OPV producirá casos de poliomielitis paralítica en tasas menores a 1 caso por millón de niños vacunados.

Métodos: Reportamos cinco casos de poliomielitis paralítica asociados a las vacunaciones de OPV en el Perú entre los años 2009 y 2011. Se describieron los síntomas, el antecedente de vacunación, los resultados de los exámenes diagnósticos y los análisis de ADN del virus.

Resultados: Se describieron cinco casos de parálisis infantil en el periodo 2009-2011. En dos de los casos reportados se aisló poliovirus del LCR. En el tercer caso se aisló un virus de la familia Enterovirus. En los otros dos casos no se pudo determinar el tipo de virus.

Conclusiones: La identificación de un caso derivado de un caso en el ámbito local permitió el conocimiento del caso y la clasificación final. El error diagnóstico inicial como “encefalitis post-vacunal” ocasionó una inadecuada respuesta política y de la presentante, produciéndose un impacto sanitario negativo. Las coberturas de vacunación para hepatitis B y para otras vacunas cayeron a niveles críticos por más de un año en el departamento de Ica.
suggestive of lower motor neurone weakness but we did not have any further details.

Triplication of PMP22 region presenting with classical clinical and electrophysiological signs of CMT-1A has been described only once before to our knowledge. Whether it alters the long-term outcome of the condition is not known.

### P306 INFANTILE AXONAL NEUROPATHY - A CASE SERIES

Nikil Sudarsan, Evageline Wassmer, Sunny Philip, Shakti Agrawal. Department of Neurology, Birmingham Children’s Hospital, UK, United Kingdom

**Introduction:** Early onset axonal neuropathies are a rare group of disorders associated with muscle weakness and early mortality. It is often difficult to elucidate an exact genetic mutation, largely due to a wide range of possible mutations. This poses ethical dilemma for professionals and families, in continuing (or withdrawing) intensive care due to scarce information regarding prognosis.

**Methods:** Review of case notes, investigations, clinical history and examination of patients.

**Case Series:** We present the clinical presentations, neurophysiological findings, and course of four infants with severe axonal neuropathy. All four infants presented within the first few weeks of life with poor feeding and or respiratory difficulties. Two needed assisted ventilation, one from birth and the other from 3 months of age, until the point they died. Neurophysiology showed purely motor axonal neuropathy in two infants and a sensorimotor axonal neuropathy in the other two. MRI of brain and spine were normal in three cases and showed cerebellar hypoplasia in one. Three of them died between 4 and 6 months and one survives with significant weakness at sixteen months. Extensive genetic investigations did not reveal any specific mutation. Nerve biopsy was performed in two of them; one showed giant axonal neuropathy and the other showed axonal neuropathy with no other diagnostic features.

**Conclusion:** This paper highlights the high rate of early mortality and the extremely low chance of finding a definitive cause in axonal neuropathies in infants. It also addresses the ethical issues that families and professionals face in managing such infants.

### P307 PREPUBERTAL MYASTHENIA GRAVIS - IS INFECTION A TRIGGER OR THE CAUSE?

Sandya Tirupathi, Clare Loughran, Lyndsey Thompson. Royal Belfast Hospital for Sick Children Belfast, United Kingdom

**Objective:** Myasthenia gravis (MG) is an acquired autoimmune disorder of neuromuscular junction. Prepubertal children have a higher prevalence of ocular symptoms (OMG), lower frequency of acetylcholine receptor antibodies (AChR), and higher probability of achieving remission. We define presenting features and outcomes in our cohort.

**Methods:** We identified four prepubertal children with MG.

**Results:** Two males (M) and two females (F) with age of onset at 3 (F1), 2.5 (M1), 1.5 (F2), and 10y (M2) were reviewed. All patients were tensilon test positive. They had electrophysiology, including the repetitive nerve stimulation (RNS) tests. All patients had antibodies sent against AChR and Muscle specific Kinase (MuSK). Neuroimaging was done in three who presented with acute symptoms.

Three children (F1, M1, F2) presented acutely following viral infections which included Chicken pox, diarrhoeal illness and herpetic stomatitis respectively. F1 presented with ptosis and bilateral divergent squint and was initially diagnosed with internuclear ophthalmoplegia. Months later was diagnosed with OMG following positive tensilon. AChR antibodies are positive. Ptosis resolved with pyridostigmine but the ophthalmoplegia partially persists. F2 and M1 presented with ptosis and generalised weakness (M1). RNS showed a decrement in both. Both are antibody negative. Symptoms resolved with pyridostigmine in both.

M2 presented insidiously, is antibody positive and has a refractory course needing thymectomy, plasma exchange and rituximab.

**Discussion:** Could the relatively higher remission rates and lower levels of acetylcholine receptor antibodies seen in prepubertal MG be related to a post infectious autoimmune phenomenon? Or is there a genetic predisposition which is triggered by infection? A high index of suspicion is necessary to make an early diagnosis.